The Value of Prevention: Experiences of a Public Health Agency
P. Corso,S. Thacker,J. Koplan
DOI: https://doi.org/10.1177/027298902237712
2002-09-01
Medical Decision Making
Abstract:I his recent article about the history of the Society for Medical Decision Making (SMDM), Fryback notes that at their 1st meeting in 1979, members of SMDM discussed the sensibility of devoting careers to the use of newly developing and not very popular quantitative methods to guide medical decision making. On the prevention side of decision making, we had similar discussions. David Sencer, former director of the Centers for Disease Control and Prevention (CDC), wrote in 1975 that “From a public investment standpoint, we need to employ an economic-type of thinking in planning disease prevention programs.” His article briefly summarized how benefit-cost analysis, as a “type of policy analysis still in a developing stage,” could be useful for developing priority criteria and as a tool to determine “the dollar worth of a prevention expenditure.” As the recent essays published in Medical DecisionMaking reflect on the beginnings and future of medical decision making, in this article we will similarly describe how CDC has used formal economic methods for public health decision making. Prevention in health is best understood in the context of 3 levels of prevention—primary, secondary, and tertiary. Primary prevention attempts to reduce the incidence of disease and injury (e.g., polio vaccination), whereas secondary prevention is focused on early detection and prompt and effective interventions (e.g., screening for colon cancer). Tertiary prevention provides measures to reduce or eliminate long-term impairments and disabilities (e.g., screening for retinal complications of diabetes). CDC programs include a full spectrum of contemporary public health concerns, for example, occupational safety and health, environmental health, chronic diseases, maternal and child health, injuries and violence, and infectious diseases. These programs are delivered primarily through state and local health agencies. Agency activities range from providing leadership, conducting applied research, building capacity and a public health infrastructure, to developing standards and guidelines and disseminating credible public health information. Public health, as with all sectors of public expenditure and all aspects of health care, is scrutinized for its value, both internally—how does one public health intervention compare in value with another—and externally—how does a public health intervention compare in societal value with one competing for resources in education, transportation, and security? To meet these needs, the expansion of sciences at CDC has increased from the traditional applications of microbiology, epidemiology, and statistics to behavioral and social sciences, program evaluation, economic evaluation, and the decision sciences. To provide information on the economic feasibility of interventions of interest, CDC has relied increasingly on the use of cost analysis, cost-effectiveness analysis, cost-benefit analysis, and the decision sciences. This article provides a historical perspective on the use of economic tools at CDC, which includes several examples of economic evaluations that have been instrumental in influencing public health policy; it will describe the present use of economic evaluation at CDC by highlighting some challenges encountered in its use. Future directions for research and methodologic improvements also are discussed.